| Recruiting | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cel Mantle Cell Lymphoma (MCL) | Phase 2 | 2025-09-30 |
| Recruiting | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients W Large B Cell Lymphoma | Phase 2 | 2025-08-04 |
| Recruiting | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cel DIFFUSE LARGE B-CELL LYMPHOMA | Phase 2 | 2024-11-20 |
| Recruiting | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant Hodgkin Lymphoma, Adult | Phase 2 | 2020-06-01 |
| Unknown | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) Hodgkin Lymphoma | Phase 1 / Phase 2 | 2018-08-08 |
| Terminated | DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB CCO | — | 2018-05-01 |
| Active Not Recruiting | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL Mantle Cell Lymphoma | Phase 2 | 2016-05-18 |
| Completed | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT Diffuse Large B-Cell Lymphoma | Phase 2 | 2016-04-07 |
| Unknown | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligib Mantle-cell Lymphoma | Phase 2 | 2015-03-01 |
| Completed | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma CLASSICAL HODGKIN LYMPHOMA | Phase 1 / Phase 2 | 2014-11-11 |
| Completed | Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B Lymphoma | Phase 2 | 2013-10-11 |
| Completed | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Diffuse, Large B-Cell, Lymphoma | Phase 2 | 2013-10-03 |
| Completed | Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B-Cell Lymphomas | Phase 2 | 2012-04-04 |
| Completed | Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant Bendamustine, Conditioning Therapy, Autologous Stem Cell Transplant | Phase 2 | 2011-05-01 |
| Completed | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Phase 2 | 2011-04-01 |
| Completed | Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | 2011-01-01 |
| Completed | Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma Hodgkin Disease | Phase 2 | 2010-07-01 |
| Completed | R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial Non-Hodgkin's Lymphoma | Phase 2 | 2009-07-01 |
| Completed | Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lympho MALT LYMPHOMA | Phase 2 | 2009-05-01 |
| Completed | Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Diffuse Large B-cell Lymphoma | — | 2009-02-01 |
| Completed | Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2008-01-01 |
| Completed | Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hod Non-Hodgkin Lymphoma | Phase 2 | 2007-11-01 |
| Completed | Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cel Diffuse Large B-cell Lymphoma, Follicular Grade 3B Lymphoma | Phase 2 | 2007-06-01 |
| Terminated | Cyclosporine Plus Methotrexate or Alemtuzumab Unrecognized Condition: Mature B or T-cell Neoplasm | Phase 2 | 2003-09-01 |